<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOCETAXEL</span><br/>(doc-e-tax'el)<br/><span class="topboxtradename">Taxotere<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">taxane agent</span><br/><b>Prototype: </b>Paclitaxel<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg, 80 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Docetaxel is a semisynthetic analog of paclitaxel. Potential advantages over paclitaxel are greater antitumor activity and
         lower toxicity potential. Docetaxel, like paclitaxel, binds to the microtubule network essential for interphase and mitosis
         of the cell cycle.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Docetaxel stabilizes the microtubules involved in cell division and prevents their normal functioning, which results in inhibiting
         mitosis in cells.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Metastatic breast cancer, metastatic prostate cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to docetaxel or other drugs formulated with polysorbate 80, paclitaxel, neutrophil count 3, biliary tract disease, hepatic disease, jaundice, neutropenia, intramuscular injections, thrombocytopenia, lactation, pregnancy
         (category D), acute infection.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bone marrow suppression, bone marrow transplant patients, CHF, ascites, peripheral edema, pleural effusion, radiation therapy,
         pulmonary disorders, acute bronchospasm; cardiac tamponade, dental disease, dental work, herpes infection, hypotension, infection.
         Safety and effectiveness in children not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 60100 mg/m<sup>2</sup> once every 3 wk (premedicate patients with dexamethasone 8 mg b.i.d. <small>x</small> 5 d, starting 1 d prior to docetaxel)<br/><br/><span class="indicationtitle">Prostate Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 75 mg/m<sup>2</sup> over 1 h every 21 d plus prednisone (5 mg PO twice daily) for 10 cycles (premedicate patients with dexamethasone 8 mg q12h,
               3h, and 1h<b></b> prior to starting docetaxel infusion)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: If drug contacts skin during preparation, wash immediately with soap and water.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Bring vials to room temperature for 5 min; add provided diluent, gently rotate for 15 s; let stand until surface foam dissipates. Inject required amount of diluted solution into a 250-mL, or larger, bag of NS or D5W; the final concentration should not
                  exceed 0.9 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags and administer through polyethylene-lined administration
                  sets. Do not use PVC administration sets or containers.  Mix completely by manual rotation. Use within 4 h (including the 1 h infusion time). 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span>  Give at a constant rate over 1 h. Administer <small>ONLY</small> after premedication with corticosteroids to prevent hypersensitivity. Reduce dose by 25% following severe neutropenia (3) for 7 d or longer for febrile neutropenia, severe cutaneous reactions, or severe peripheral neuropathy. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Refrigerate vials at 2°8° C (36°46° F). Protect from light. Do not store in PVC bags. Store
            diluted solutions in refrigerator or at room temperature for 8 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Paresthesia, pain, burning sensation, weakness, confusion. <span class="typehead">CV:</span> Hypotension, <span class="speceff-common">fluid retention (peripheral edema, weight gain),</span> pleural effusion. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea, stomatitis,</span> abdominal pain; increased liver function tests (AST or ALT). <span class="typehead">Hematologic:</span>
<span class="speceff-both">Neutropenia, leukopenia, thrombocytopenia, anemia</span>, febrile neutropenia. <span class="typehead">Skin:</span> Rash, localized eruptions, desquamation, <span class="speceff-common">alopecia</span>, nail changes (hyper/hypopigmentation, onycholysis). <span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Hypersensitivity reactions,</span> infusion site reactions (hyperpigmentation, inflammation, redness, dryness, phlebitis, extravasation). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Possibility of interacting with other drugs metabolized by the cytochrome P4503A system <b>(cyclosporine,</b>
<b>erythromycin,</b>
<b>ketoconazole,</b>
<b>troleandomycin).</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 97% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P4503A isoenzymes. <span class="typehead">Elimination:</span> 80% eliminated in feces, 20% renally excreted. <span class="typehead">Half-Life:</span> 11.1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor bilirubin, AST or ALT, and alkaline phosphatase prior to each drug cycle. Generally, do not give to patients
            with elevations of bilirubin or with significant elevations of transaminases concurrent with elevations of alkaline phosphatase.
            Monitor frequently CBCs with differential. Withhold drug if platelets 3.
         </li>
<li>Monitor for S&amp;S of hypersensitivity (see Appendix F), which may develop within a few minutes of initiation of infusion. It
            is usually not necessary to discontinue infusion for minor reactions (i.e., flushing or local skin reaction).
         </li>
<li>Assess throughout therapy and report cardiovascular dysfunction, respiratory distress; fluid retention; development of neurosensory
            symptoms; severe, cutaneous eruptions on feet, hands, arms, face, or thorax; and S&amp;S of infection.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn common adverse effects and measures to control or minimize them when possible. Report immediately any distressing adverse
            effects.
         </li>
<li>
            							Note: It is extremely important to comply with corticosteroid therapy and monitoring of lab values.
            						
         </li>
<li>Avoid pregnancy during therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>